Dermatology · Papulosquamous Eruptions
The facts most likely to be tested
The initial clinical presentation is a single, large, erythematous, scaly plaque known as a herald patch.
The secondary eruption follows the herald patch by 1 to 2 weeks and typically manifests as a diffuse, salmon-colored papulosquamous rash.
The rash characteristically follows the Langer lines of the skin, resulting in a Christmas tree distribution on the back.
The lesions exhibit a classic collarette of scale, where the scale is located at the periphery of the plaque with a clear center.
Pityriasis rosea is strongly associated with reactivation of Human Herpesvirus 6 (HHV-6) or 7 (HHV-7).
The condition is self-limiting and typically resolves spontaneously within 6 to 8 weeks without the need for specific medical intervention.
Secondary syphilis must be excluded in patients with a palmar or plantar rash or generalized lymphadenopathy, as it is the primary differential diagnosis.
Vignette unlocked
A 22-year-old male presents to the clinic complaining of a rash on his trunk that started 2 weeks ago. He reports that the rash began as a single, large, oval-shaped, scaly patch on his upper back. Since then, numerous smaller, salmon-colored papules have appeared across his torso. Physical examination reveals a Christmas tree distribution of lesions on his back, each with a collarette of scale. He denies fever, malaise, or recent sexual activity.
What is the most likely diagnosis?
Pityriasis rosea
The diagnosis is based on the classic progression from a herald patch to a Christmas tree distribution of lesions with a collarette of scale, which is pathognomonic for pityriasis rosea.
Full handout
High yield triage
Etiology / Epidemiology
Common in adolescents and young adults; associated with HHV-7 or HHV-6 reactivation.
Clinical Manifestations
Starts with a herald patch followed by a Christmas tree distribution of scaly papules.
Diagnosis
Primarily a clinical diagnosis; biopsy is reserved for atypical cases.
Treatment
Self-limiting; supportive care with topical steroids or antihistamines for pruritus.
Prognosis
Spontaneous resolution in 6–8 weeks; no long-term sequelae.
Full handout
Epidemiology & Etiology
Typically affects individuals aged 10–35 years. Often presents in the spring or autumn. While the exact trigger is debated, it is strongly linked to HHV-7 and HHV-6 viral reactivation.
Pertinent Anatomy
The eruption follows the Langer's lines of skin tension. This anatomical distribution creates the characteristic Christmas tree pattern on the trunk.
Pathophysiology
The condition begins with a primary viral infection or reactivation. This triggers a cell-mediated immune response leading to the characteristic inflammatory skin eruption. The process is self-limiting as the host immune system clears the viral load.
Clinical Manifestations
The herald patch is a solitary, large, salmon-colored scaly plaque that precedes the generalized eruption by 1–2 weeks. The secondary phase features smaller, oval, collarette-scaled lesions. Red flags include lesions on the palms or soles, which should prompt testing for secondary syphilis.
Diagnosis
Diagnosis is clinical. If the presentation is atypical or persistent, a skin biopsy is the gold standard to rule out other dermatoses. Serologic testing for RPR/VDRL is mandatory if the patient is sexually active to exclude syphilis.
Treatment
No curative treatment is required as the condition is self-limiting. For symptomatic relief of pruritus, use topical corticosteroids or oral antihistamines. Avoid systemic steroids as they are unnecessary for this benign, transient condition.
Prognosis
Lesions typically resolve spontaneously within 6–8 weeks. Post-inflammatory hyperpigmentation may persist in darker skin tones, but scarring is rare.
Differential Diagnosis
Secondary Syphilis: involves palms and soles
Tinea Corporis: central clearing and fungal hyphae on KOH prep
Guttate Psoriasis: thicker, micaceous scale
Nummular Eczema: intensely pruritic, coin-shaped lesions without collarette scale
Drug Eruption: temporal association with new medication initiation